Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial중등도 내지 중증 CovID19 질병을 가진 입원 환자의 치료를위한 피하 Sarilumab : 실용적이고 임베디드 무작위 임상 시험Randomized Controlled Trial Published on 2022-02-252022-09-10 Journal: PLoS ONE [Category] 임상, 진단, 치료제, [키워드] adaptive added addition adopted anti-IL-6R Anti-inflammatory drugs antibody Antiviral Arm benefit clinical criteria Clinical management contribute Controlled trial COVID-19 COVID-19 disease COVID19 Data monitoring committee death Dexamethasone diagnostic diagnostic test dose Effectiveness EHR Electronic health record Eligible patients evaluated event Health health record hospitalized COVID-19 patients hospitalized patient IL-6R Importance include information initial Inpatient Inpatients intubation majority measure mechanical ventilation moderate moderate to severe numbers of patient occurred Open-label outcome participant Patient patients hospitalized positive Pragmatic primary endpoint Primary outcome Probability randomization Randomized randomized clinical trial randomized trial Remdesivir respiratory respiratory compromise Result sarilumab SARS-CoV-2 setting severe COVID-19 severe COVID-19 disease Standard of care Subcutaneous subcutaneous injection the primary endpoint Treatment Trial was increased [DOI] 10.1371/journal.pone.0263591 PMC 바로가기 [Article Type] Randomized Controlled Trial
Adipose tissue in COVID-19: detection of SARS-CoV-2 in adipocytes and activation of the interferon-alpha responseCOVID-19의 지방 조직: 지방 세포에서 SARS-CoV-2 감지 및 인터페론-알파 반응 활성화Original Article Published on 2022-02-152022-09-10 Journal: Journal of Endocrinological Investigation [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료기술, 치료법, [키워드] ACE2 gene activate Activation adipocyte adipocytes adipose Adipose tissue Adults age and sex Alpha alteration appear association Autopsy BMI cardiac death cause causes Cell characterization Control controls COVID-19 COVID-19 case COVID-19 cases COVID-19 cohort cytoplasm death Deceased fat Features form Genome IFN IFN-alpha Immune transcriptome immune-related genes infect infiltrating Inflammatory mediators interferon interferon-alpha investigation leukocyte leukocytes lung parenchyma mechanism mediators moderate moderate to severe nucleocapsid antigen obesity objective parenchymal Pathogenesis pathway PCR progression proportion Result risk factor RT-PCR SARS-CoV-2 SARS-CoV-2 genome severe disease severe forms of COVID-19 specimen Subcutaneous subcutaneous fat subject sudden cardiac death the SARS-CoV-2 the SARS-CoV-2 genome tissue Transcription trauma upregulation virus virus antigen virus antigens [DOI] 10.1007/s40618-022-01742-5 PMC 바로가기 [Article Type] Original Article
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2렘데시비르 피하 투여로 SARS-CoV-2 접종한 붉은털원숭이의 간질성 폐렴 예방Article Published on 2022-02-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 치료제, [키워드] absence administer administration animal animal model Antiviral caused COVID-19 COVID-19 patient disease Efficacy hospitalized patients in vivo inoculated interstitial pneumonia intravenously Lower respiratory tract lower respiratory tract disease macaque macaques post inoculation Prevent PROTECT reduced reduction Remdesivir Respiratory disease rhesus rhesus macaque SARS-CoV-2 SARS-COV-2 infection Subcutaneous subcutaneous administration tested treated Treatment utility virus virus replication [DOI] 10.1016/j.antiviral.2022.105246 PMC 바로가기 [Article Type] Article
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial초기 무증상 SARS-CoV-2 감염에서 증상이 있는 COVID-19 발병에 대한 피하 카시리비맙 및 임데비맙 항체 조합 대 위약의 효과: 무작위 임상 시험Clinical Trial Published on 2022-02-012022-09-12 Journal: JAMA [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 1:1 age anti-SARS-CoV-2 antibody combination Asymptomatic asymptomatic infection baseline Casirivimab clinical Combination Contact COVID-19 development dose double-blind Effect Efficacy efficacy analysis efficacy end point eligible enrolled evaluate the effect event Follow-up household contact Imdevimab incidence index case individual Odds ratio outcome participant phase 3 trial Placebo placebo-controlled polymerase chain positive Positive test Prevent prevented primary end point progression proportion Randomized receive receiving reduce reduced reduction in reported Result risk Romania RT-qPCR SARS-CoV-2 SARS-COV-2 infection seronegative seronegative participant significantly Subcutaneous symptom duration symptomatic symptomatic disease symptomatic participant symptomatic SARS-CoV-2 infection Treatment treatment-emergent adverse event Viral load women [DOI] 10.1001/jama.2021.24939 PMC 바로가기 [Article Type] Clinical Trial
Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trialCOVID-19의 피하 인터페론 베타-1a: 중재 시험의 잿더미를 긁어모으다Comment Published on 2021-12-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] SARS, 신약개발, 치료제, [키워드] interferon Intervention Subcutaneous Trial [DOI] 10.1016/S2213-2600(21)00412-4 PMC 바로가기 [Article Type] Comment
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial중증 COVID-19에서 고용량 인터페론 베타 1-a가 저용량 인터페론 베타 1-a에 비해 유익한 효과에 대한 조사: COVIFERON II 무작위 대조 시험Clinical Trial Published on 2021-10-012022-09-11 Journal: International immunopharmacology [Category] 임상, 치료제, [키워드] assigned clinical Clinical improvement clinical trial control group coronavirus disease Coronavirus disease 2019 COVID COVID-19 Effect Effectiveness eligible patient Eligible patients High-dose hospitalized patient hospitalized patients IFN-β IMPROVE improvement injection interferon interferon beta Interferon-beta Interferon-β 1a Intervention intervention group Kaletra Lopinavir Lopinavir/ritonavir low dose low-dose median time moderate moderate to severe Mortality mortality rate mortality rates Patient patients with COVID-19 public health randomization Randomized Randomized controlled trial Randomly receive Recigen reduction Registered Ritonavir SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections severe COVID-19 significant effect Subcutaneous subcutaneous injections The COVIFERON therapeutic time treat treated Trial TTCI TTIC twice a day [DOI] 10.1016/j.intimp.2021.107916 PMC 바로가기 [Article Type] Clinical Trial
Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells Research Published on 2021-09-272022-10-05 Journal: Nature biomedical engineering [Category] 치료제, [키워드] Activation activation and expansion Amino acid Arthritis Autoimmune diseases bind binding Cell cytokine defined disease dose ENhance glycol Host IL-2 IL-2 receptor immune Immunosuppression injection mouse model PEGylation Regulatory Regulatory T cell selective Subcutaneous sustained therapeutic therapeutic efficacy therapeutic window Treatment Treg Treg cells trimeric viral infection [DOI] 10.1038/s41551-021-00797-8 [Article Type] Research
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19코로나19 예방을 위한 피하 REGEN-COV 항체 조합Randomized Controlled Trial Published on 2021-09-232022-09-12 Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, 진단, 치료법, [키워드] 1:1 acute respiratory syndrome Administered age assigned Asymptomatic Combination Contact coronavirus coronavirus disease death diagnosis of SARS-CoV-2 diagnostic dose efficacy end point enrolled high risk Hospitalization household contact Immunity Infection Local matching placebo monoclonal antibody participant Participants Placebo Prevent prevented randomization Randomly receive reduce reduced REGEN-COV Regeneron Pharmaceutical REGN-CoV2 resolution of symptom risk risk reduction SARS-CoV-2 SARS-COV-2 infection Seronegativity shown stratified Subcutaneous subcutaneous injection subsequent symptomatic symptomatic and asymptomatic symptomatic COVID-19 symptomatic disease symptomatic SARS-CoV-2 infection the median the placebo group toxic effect uninfected Viral load [DOI] 10.1056/NEJMoa2109682 PMC 바로가기 [Article Type] Randomized Controlled Trial
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge이중 항원 COVID-19 백신 경구 부스트가 포함된 피하 프라임 전달은 SARS-CoV-2 도전으로부터 NHP를 보호합니다Immunology Published on 2021-09-162022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법, [키워드] 24 hour 24 hours Adenovirus Against anti-S IgG boost challenge COVID-19 COVID-19 vaccine delivery demonstrated dual antigen effective elicited enhanced followed by fusion helper cell Immunity inhibited injection Lower respiratory tract lung MHC class MHC class II nasal passages Neutralizing NHP non-human primate (NHP) oral platform protection Protein respiratory responses rhesus macaque rhesus macaques SARS-CoV-2 SARS-CoV-2 challenge SARS-CoV-2 spike protein serotype Spike protein Stimulation Subcutaneous T helper cell T-cell T-cell Response T-cell responses TCID the viral nucleocapsid undetectable upper and lower respiratory tracts Vaccine vaccine antigen Viral viral replication [DOI] 10.3389/fimmu.2021.729837 PMC 바로가기 [Article Type] Immunology
COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?Case Report Published on 2021-07-292022-10-31 Journal: Journal of Ophthalmic & Vision Research [Category] COVID-19, [키워드] Acute Zonal Occult Outer Retinopathy antibody Arteritic Anterior Ischemic Optic Neuropathy Autoimmune AZOOR correlation COVID-19 COVID-19 mRNA Vaccination COVID-19 vaccination CRP demonstrated Dexamethasone diagnosed ESR eye eyes female GCA giant cell arteritis healthy IL-6 inflammatory disease injection Intraocular pressure intravitreal ischemic optic neuropathy loss of vision mechanism Moderna mRNA mRNA vaccine nasal occurred ocular pallor Patient performed Pfizer pupillary receiving recombinant report SARS-CoV-2 side Subcutaneous Symptom T-helper 1 Temporal Tocilizumab treated visual acuity [DOI] 10.18502/jovr.v16i3.9443 PMC 바로가기 [Article Type] Case Report